ArticleFrontiers in pharmacology2025
Exploration of the potential neurotransmitter or neuromodulator-like properties of harmine: evidence from synthesis to synaptic modulation.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- In Silico and In Vitro Evaluation of Calm Supplement Constituents on Antidepressant-Related Molecular Targets and Neuroplasticity-Associated Gene Expression.Biomedicines · 2026Article
- Harmaline and the gut-brain-immune axis: a novel therapeutic avenue in neuroinflammation and ulcerative colitis.Inflammopharmacology · 2026Review
- International Union of Basic and Clinical Pharmacology. CXXII. Applying an objective evaluation to the status of class A orphan G protein-coupled receptors.Pharmacological reviews · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The discovery of new neurotransmitters is crucial for the in-depth understanding of neural signal transmission, neurological disorders, and relevant treatment strategies. Emerging evidence has indicated that harmine is an important endogenous compound, and its level is closely related to different physiological and disease states. Inspired by this, we propose a hypothesis that harmine may be a potential neurotransmitter or neuromodulator and display neurotransmitter or neuromodulator-like properties. This study aims to explore the potential properties of harmine as a neurotransmitter or neuromodulator according to the essential criteria for neurotransmitters and neuromodulators. Methods: Candidate proteins for the biosynthesis of harmine were searched by local BLAST. The target protein was then recombinantly expressed, purified, and functionally validated. Subsequently, the release, metabolism, and uptake pathways of harmine were investigated using rat brain synaptosomes and primary neural cells through mass spectrometry analysis. A human proteome microarray was employed to screen for harmine-binding receptors, followed by experimental validation. Results: Adipocyte plasma membrane-associated protein isoform X1 (APMAP-X1) could effectively catalyze the Pictet-Spengler reaction in mammals to generate tetrahydroharmine, which was subsequently oxidized by myeloperoxidase (MPO) to produce harmine. Moreover, harmine could be metabolized, taken up, and released within the synaptic cleft, fulfilling the conditions for clearance and release within the synaptic cleft. Harmine also regulated the expression of neurotransmitter transporters, implying its potential neuromodulatory properties. G protein-coupled receptor 85 (GPR85) and chloride intracellular channel 2 (CLIC2) were receptors targeted by harmine in the central nervous system. Functional verification results confirmed that harmine exerted an inhibitory effect on the GPR85 and could induce cellular depolarization. Conclusion: Current findings provide preliminary evidence that harmine may exhibit neurotransmitter-like properties in certain respects and support its role as an endogenous neuromodulator. However, direct evidence supporting harmine as a neurotransmitter remains limited. Further studies are needed to clarify the precise mechanisms of harmine in neurotransmission. Our study provides a new perspective for researchers on exploring novel endogenous molecules and their significance in neurophysiology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.